Accounts receivable - other Accounts Receivable, Net, Current Accrued interest income Accumulated other comprehensive loss Additional paid-in capital Capital expenditures Payments to Acquire Productive Assets Restricted Stock [Member] Stock Options [Member] CONDENSED BALANCE SHEETS (Unaudited) [Abstract] Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash and Cash Equivalents, at Carrying Value Increase in accounts payable, accrued expenses, and other liabilities Decrease (increase) in accounts receivable Increase (Decrease) in Accounts Receivable (Increase) decrease in prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Changes in assets and liabilities Legal Matters Commitments and Contingencies Disclosure [Text Block] Common Stock, shares authorized (in shares) Common Stock, shares issued (in shares) Common Stock, shares outstanding (in shares) Common Stock Common Stock, Value, Issued Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Cost of goods sold Cost of goods sold related to ARCALYST sales Expenses Total current liabilities Liabilities, Current Current liabilities Liabilities, Current [Abstract] Debt Securities [Member] Deferred revenue [Abstract] Deferred revenue - other, current portion Deferred Revenue, Current Deferred revenue - other Deferred Revenue, Noncurrent Stock-based compensation charges Non-cash compensation expense Share-based Compensation Equity Securities [Member] CONDENSED STATEMENTS OF OPERATIONS (Unaudited) [Abstract] Income Taxes Income Tax Disclosure [Text Block] Interest expense Interest Expense Finished goods Raw materials Work in process Inventories included in prepaid expenses and other current assets Total liabilities Liabilities Total liabilities and stockholders' equity Liabilities and Equity LIABILITIES and STOCKHOLDERS' EQUITY LIABILITIES and STOCKHOLDERS' EQUITY Available-for-sale marketable securities Available-for-sale Securities Marketable securities Marketable Securities, Current Marketable Securities [Abstract] Marketable securities Marketable Securities, Noncurrent Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from financing activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from investing activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities Net loss Net loss Net loss (Numerator) Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Recently Issued Accounting Standards [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Recently Issued Accounting Standards Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Total other income (expense) Nonoperating Income (Expense) Other income (expense) Investment income Other non-cash charges and expenses, net Other Noncash Expense Inventories included in other assets Loss from operations Operating Income (Loss) Total revenues Revenues Revenues Revenues [Abstract] Interim Financial Statements Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Change in net unrealized gain (loss) on marketable securities Change in net unrealized gain (loss) on marketable securities, net of tax effect Preferred stock, shares authorized (in shares) Preferred stock, issued (in shares) Preferred stock, outstanding (in shares) Preferred stock, par value (in dollars per share) Net proceeds from the issuance of Common Stock Sales or maturities of marketable securities Property, plant, and equipment, at cost, net of accumulated depreciation and amortization Property, Plant and Equipment, Net Purchases of marketable securities Payments to Acquire Marketable Securities Accounts receivable from Sanofi Payments in connection with capital lease obligation Repayments of Long-term Capital Lease Obligations Accumulated deficit Retained Earnings (Accumulated Deficit) Contract research and other Technology licensing Revenue recognition, deferred revenue Net product sales ARCALYST net product sales Inventory Inventory Disclosure [Text Block] Selling, general, and administrative CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) [Abstract] Comprehensive Loss [Abstract] Statement of Stockholders' Equity [Abstract] Stockholders' equity Stockholders' equity Total current assets Assets, Current Current assets Assets, Current [Abstract] Municipal Bonds [Member] U.S. Government Obligations [Member] Common Stock [Member] Research and development Schedule of Available-for-sale Securities [Table] Major Types of Debt and Equity Securities [Domain] Amortized Cost Basis - Maturities within one year Amortized Cost Basis - Maturities between one and five years Amortized Cost Basis - Total Available-for-sale Securities, Debt Maturities, Amortized Cost Basis Fair Value - Maturities within one year Fair Value - Maturities between one and five years Debt Securities, Amortized Cost Basis [Abstract] Debt Securities, Fair Value [Abstract] Continuous Unrealized Loss Position, Fair Value [Abstract] Fair Value - Less than 12 Months Fair Value - 12 Months or Greater Fair Value - Total Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value Continuous Unrealized Loss Position, Aggregate Losses [Abstract] Fair Value - Total Available-for-sale Securities, Debt Securities Fair value of equity securities Total assets Assets Other long term liabilities Other Liabilities, Noncurrent Statement [Table] Antidilutive Securities, Name [Domain] ASSETS Assets [Abstract] Statement [Line Items] Fair value, assets measured on recurring basis Fair Value, Inputs, Level 1 [Member] Fair Value Measurements at Reporting Date Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Measurements at Reporting Date Using Significant Other Observable Inputs (Level 2) [Member] Class of Stock [Domain] Statement of Cash Flows Cash Flow, Supplemental Disclosures [Text Block] Supplemental disclosure of noncash investing and financing activities [Abstract] Class A Stock [Member] Increase (decrease) in stockholders' equity [Roll Forward] (Decrease) increase in deferred revenue Deferred ARCALYST net product sales revenue Deferred ARCALYST net product sales Other assets Other Assets, Noncurrent Antidilutive securities [Abstract] Weighted average number, in thousands (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Per Share Data [Abstract] Antidilutive securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Previously deferred ARCALYST net product sales recognized as revenue Net loss before income tax benefit Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis] Schedule of Available-for-sale Securities [Line Items] Class of Stock [Axis] Common Stock, par value (in dollars per share) Total stockholders' equity Balance Balance Stockholders' Equity Attributable to Parent Income tax benefit Preferred stock Preferred Stock, Value, Issued Components of comprehensive loss, net of tax [Abstract] Statement, Equity Components [Axis] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Income (Loss) [Member] Equity Component [Domain] Sanofi collaboration revenue Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution Issuance of restricted Common Stock under Long-Term Incentive Plan Issuance of Common Stock in connection with exercise of stock options, net of shares tendered Conversion of Class A Stock to Common Stock Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares) Issuance of restricted Common Stock under Long-Term Incentive Plan (in shares) Issuance of Common Stock in connection with exercise of stock options, net of shares tendered (in shares) Conversion of Class A Stock to Common Stock (in shares) U.S. Government Guaranteed Collateralized Mortgage Obligations [Member] Mortgage-Backed Securities [Member] Comprehensive Loss [Member] Total expenses Costs and Expenses Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Other-than-temporary impairment charge on Level 2 marketable security Balance (in shares) Balance (in shares) Shares, Issued Per Share Data Earnings Per Share [Text Block] Depreciation and amortization Commitments and contingencies Marketable Securities Marketable Securities [Text Block] Restricted cash and marketable securities Restricted Cash and Investments, Noncurrent Adjustments to reconcile net loss to net cash used in operating activities Total adjustments Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Accounts payable and accrued expenses Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Accounts payable Accrued payroll and related costs Other accrued expenses and liabilities Accounts payable and accrued expenses [Abstract] Accrued Company 401(k) Savings Plan contribution expense Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Type of Arrangement and Non-arrangement Transactions [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Measurements, Recurring [Member] Measured on a Recurring Basis [Member] Revenue Recognition, Milestone Method [Table] Revenue Recognition, Milestone Method [Line Items] Description of the overall arrangement Description of milestone Unrealized Gains - Total Available-for-sale Securities, Gross Unrealized Gains Accounts Payable and Accrued Expenses [Abstract] Accounts Payable and Accrued Expenses Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Fair Value, Hierarchy [Axis] Fair Value by Measurement Frequency [Axis] Fair value and unrealized losses of marketable securities Accounts payable and accrued expenses Legal Matters [Abstract] Income Taxes [Abstract] Inventory [Abstract] Cost basis of equity securities Components of comprehensive loss, net of tax Assets, fair value disclosure [Abstract] Assets, Fair Value Disclosure [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Unrealized (Losses) - Total Available-for-sale Securities, Gross Unrealized Losses Arrangements and Non-arrangement Transactions [Domain] Basic and diluted net loss per share [Abstract] Net loss per share, basic and diluted Basic and diluted net loss per share (in dollars per share) Basic and diluted net loss per share Unrealized Gains (Losses), Net [Abstract] Unrealized Net - Total Available-for-sale Securities, Gross Unrealized Gain (Loss) Unrealized Loss - Less than 12 Months Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses Unrealized Loss - 12 Months or Greater Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses Unrealized Loss - Total Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses Marketable securities, based on contractual maturity dates Amendment Flag Current Fiscal Year End Date Document Period End Date Entity [Text Block] Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Deferred Revenue From Related Party Current The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Deferred revenue from Sanofi, current portion Deferred Revenue From Related Party Noncurrent The noncurrent portion of deferred revenue from related parties amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Deferred revenue from Sanofi Other Collaboration Revenue Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. Other collaboration revenue Weighted Average Shares Outstanding Basic And Diluted The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS. Weighted average shares outstanding, basic and diluted (in shares) Weighted average shares outstanding, basic and diluted Interim Financial Statements [Abstract] Product Revenue [Abstract] ARCALYST (rilonacept) Product Revenue [Abstract] Product Revenue [Text Block] Disclosure of the revenue recognized, net product sales, cost of goods sold, and other information related to ARCALYST product line. ARCALYST (rilonacept) Product Revenue Change In Accounting Estimate Deferred Revenue Lower Net Loss Per Share Represents the financial effect of the change in accounting estimate for deferred ARCALYST net product sales revenue. The recognition of deferred revenue lowered net loss per share for the reporting period. Change in accounting estimate, deferred revenue - lower net loss per share (in dollars per share) Sales Revenue Product Line Excluding Deferred Sales Recognized Revenue recognized during the period derived from ARCALYST product line, after deducting returns, allowances and discounts. Does not include previously deferred net product sales recognized during the period. ARCALYST net product sales, excluding deferred sales recognized as revenue Antidilutive Securities Excluded From Computation Of Earnings Per Share Weighted Average Exercise Price The weighted average price of the antidilutive securities at which grantees can acquire the shares reserved for issuance under the stock option plan. Weighted average exercise price (in dollars per share) Accrued Capital Expenditures Carrying value as of the balance sheet date of obligations incurred through that date and payable for purchases of fixed assets. Included in accounts payable and accrued expenses. Accrued capital expenditures Defined Contribution Plan Shares Contributed Shares of Common Stock contributed by the Company to the 401(k) Savings Plan in satisfaction of accrued obligations. Common Stock contributed to 401(k) Savings Plan (in shares) Facility Lease Obligations Incurred The increase during the period in facility lease obligations due to entering into new capital leases. Facility lease obligation Employee Exercises Of Stock Options Receivable Carrying amount as of the balance sheet date of amounts due the Company in connection with employee exercises of stock options. Included in other assets. Employee exercises of stock options, due to the Company Available For Sale Securities Debt Maturities Within One Year Gross Unrealized Gains Losses Net This item represents the gross unrealized gains and losses, net of debt securities which are expected to mature within one year of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Net - Maturities within one year Available For Sale Securities Debt Maturities Within One Year Gross Unrealized Loss This item represents the gross unrealized loss of debt securities which are expected to mature within one year of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized (Losses) - Maturities within one year Available For Sale Securities Debt Maturities Within One Year Gross Unrealized Gains This item represents the gross unrealized gains of debt securities which are expected to mature within one year of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Gains - Maturities within one year Available For Sale Securities Debt Maturities Between One And Three Years Amortized Cost This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after one year and through three years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Amortized Cost Basis - Maturities between one and three years Available For Sale Securities Debt Maturities Between Five And Six Years Amortized Cost This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five year and through six years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Amortized Cost Basis - Maturities between five and six years Available For Sale Securities Debt Maturities Between Five And Seven Years Amortized Cost This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five year and through seven years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Amortized Cost Basis - Maturities between five and seven years Available For Sale Securities Debt Maturities Between One And Three Years Fair Value This item represents the fair value of debt securities which are expected to mature after one year and through three years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Fair Value - Maturities between one and three years Available For Sale Securities Debt Maturities Between Five And Six Years Fair Value This item represents the fair value of debt securities which are expected to mature after five year and through six years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Fair Value - Maturities between five and six years Available For Sale Securities Debt Maturities Between Five And Seven Years Fair Value This item represents the fair value of debt securities which are expected to mature after five year and through seven years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Fair Value - Maturities between five and seven years Available For Sale Securities Debt Maturities Between One And Three Years Gross Unrealized Gains This item represents the gross unrealized gains of debt securities which are expected to mature after one year and through three years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Gains - Maturities between one and three years Available For Sale Securities Debt Maturities Between One And Five Years Gross Unrealized Gains This item represents the gross unrealized gains of debt securities which are expected to mature after one year and through five years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Gains - Maturities between one and five years Available For Sale Securities Debt Maturities Between Five And Six Years Gross Unrealized Gains This item represents the gross unrealized gains of debt securities which are expected to mature after five year and through six years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Gains - Maturities between five and six years Available For Sale Securities Debt Maturities Between Five And Seven Years Gross Unrealized Gains This item represents the gross unrealized gains of debt securities which are expected to mature after five year and through seven years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Gains - Maturities between five and seven years Available For Sale Securities Debt Maturities Between One And Three Years Gross Unrealized Loss This item represents the gross unrealized loss of debt securities which are expected to mature after one year and through three years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized (Losses) - Maturities between one and three years Available For Sale Securities Debt Maturities Between One And Five Years Gross Unrealized Loss This item represents the gross unrealized loss of debt securities which are expected to mature after one year and through five years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized (Losses) - Maturities between one and five years Available For Sale Securities Debt Maturities Between Five And Six Years Gross Unrealized Loss This item represents the gross unrealized loss of debt securities which are expected to mature after five year and through six years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized (Losses) - Maturities between five and six years Available For Sale Securities Debt Maturities Between Five And Seven Years Gross Unrealized Loss This item represents the gross unrealized loss of debt securities which are expected to mature after five year and through seven years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized (Losses) - Maturities between five and seven years Available For Sale Securities Gross Unrealized Gains Losses Net Debt Maturities Within Between One And Three Years This item represents the gross unrealized gains and losses, net of debt securities which are expected to mature between one and three years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Net - Maturities between one and three years Available For Sale Securities Gross Unrealized Gains Losses Net Debt Maturities Within Between One And Five Years This item represents the gross unrealized gains and losses, net of debt securities which are expected to mature between one and five years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Net - Maturities between one and five years Available For Sale Securities Gross Unrealized Gains Losses Net Debt Maturities Within Between Five And Six Years This item represents the gross unrealized gains and losses, net of debt securities which are expected to mature between five and six years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Net - Maturities between five and six years Available For Sale Securities Gross Unrealized Gains Losses Net Debt Maturities Within Between Five And Seven Years This item represents the gross unrealized gains and losses, net of debt securities which are expected to mature between five and seven years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. Unrealized Net - Maturities between five and seven years Fair Value Measured On Recurring Basis Us Government Obligations This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. U.S. government obligations Fair Value Measured On Recurring Basis Us Government Guaranteed Corporate Bonds This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. U.S. government guaranteed corporate bonds Fair Value Measured On Recurring Basis Us Government Guaranteed Collateralized Mortgage Obligations This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. U.S. government guaranteed collateralized mortgage obligations Fair Value Measured On Recurring Basis Municipal Bonds This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. Municipal bonds Fair Value Measured On Recurring Basis Mortgage Backed Securities This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. Mortgage-backed securities Fair Value Measured On Recurring Basis Equity Security This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis. Equity securities Number Of Level Three Marketable Securities Held Disclosure of the number of marketable securities whose fair value is measured on a recurring basis using significant unobservable inputs (Level 3), held as of the reporting date. Number of Level 3 marketable securities held Accrued Clinical Trial Expense Current Carrying value as of the balance sheet date of obligations incurred (and for which invoices have not been received) as a result of clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued clinical trial expense Accrued Property Plant And Equipment Expenditures Current Carrying value as of the balance sheet date of obligations incurred (and for which invoices have not been received) as a result of expenditures on property, plant and equipment. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued property, plant, and equipment costs Accounts Payable To Healthcare Company Current Carrying value as of the balance sheet date of amounts due to Bayer HealthCare under a Collaboration Agreement. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Payable to Bayer HealthCare Recently Issued Accounting Standards [Abstract] Carrying value of impaired marketable security The carrying value of a marketable security for which the deterioration in the credit quality from one issuer subjected the Company to the risk of not being able to recover a portion; as a result, an impairment charge was recognized. Schedule of Inventory, Current and Noncurrent [Table Text Block] Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs. Inventories Inventory Current and Noncurrent Carrying amount (lower of cost or market) as of the balance sheet date of gross inventories. Includes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer). Total inventories Maximum amount of substantive milestone payments that may be received The maximum amount in substantive milestone payments the Company may receive under the collaboration agreement. Maximum amount of substantive milestone payments that may be received in U S or European Union The maximum amount in substantive milestone payments the Company may receive under the collaboration agreement for product candidates in the U.S. or the European Union. Maximum amount of substantive milestone payments that may be received relating to marketing approvals in the U.S. or European Union Maximum number of product candidates for which substantive milestone payments may be received in U S or European Union The maximum number of product candidates for which substantive milestone payments may be received in the U.S. or European Union, under the Company's collaboration agreement. Maximum number of product candidates for which substantive milestone payments may be received relating to marketing approvals in the U.S. or European Union Maximum amount of substantive milestone payments that may be received in Japan Maximum amount of substantive milestone payments that may be received relating to marketing approvals in Japan Maximum number of product candidates for which substantive milestone payments may be received in Japan The maximum number of product candidates for which substantive milestone payments may be received in Japan, under the Company's collaboration agreement. Maximum number of product candidates for which substantive milestone payments may be received relating to marketing approvals in Japan Substantive milestone payment to Company under certain defined circumstances The amount of substantive milestone payment to be made by the collaborating company to the entity, under certain defined circumstances. The amount of substantive milestone payment to be made by the collaborating company to the entity, under certain defined circumstances. U.S. Government Guaranteed Corporate Bonds [Member] This category includes investments in debt securities issued by corporations that are guaranteed by the U.S. Government. U S Government Guaranteed Corporate Bonds [Member] Unrestricted [Member] Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements. Restricted [Member] Investments whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. Classification of Investment [Axis] This element represents the general categories of investments, which may be classified as Unrestricted or Restricted. Classification of Investment [Domain] Provides general categories of investments for which information is required or determined to be disclosed. Collaboration Agreement with Sanofi-Aventis [Member] The collaboration agreement with Sanofi-Aventis under which the Company earns substantive performance milestone payments. Collaboration Agreement with Bayer HealthCare LLC [Member] The collaboration agreement with Bayer HealthCare LLC under which the Company earns substantive performance milestone payments. Gain Loss On Investments Net realized loss on marketable securities IncreaseDecreaseInRestrictedCash Increase in restricted cash Interest Costs Capitalized Capitalized and deferred interest Marketable Securities Available For Sale Securities Policy Marketable Securities Impairment Policy Facility lease obligations, current portion Represents the current portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with a building lease. Facility lease obligations noncurrent Represents the noncurrent portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with a building lease. Facility lease obligations Payments in connection with facility lease obligations The cash outflow for payments made to lessor related to a building lease. Payments in connection with facility lease obligations Proceeds from facility lease obligations The cash inflow from proceeds received from lessor related to the construction of facilities associated with a building lease. Proceeds in connection with facility lease obligations Capital Lease Obligations in connection with acquisitions of equipment Carrying value as of the balance sheet date of acquired long-lived, physical assets used in the normal conduct of business and not intended for resale. Included in capital lease obligations and property, plant and equipment. Capital lease obligations Carrying value as of the balance sheet date of acquired long-lived, physical assets used in the normal conduct of business and not intended for resale. Included in capital lease obligations and property, plant and equipment.